Safety of prostaglandin E1 for the treatment of peripheral arterial occlusive disease in patients with congestive heart failure

American Journal of Therapeutics

Volumn 4, Issue 11-12, 1997, Pages 365-374

  Reisin, Leonardo ^a   Marmor, Alon ^a   Rabinowitz, Babeth ^a   Bernink, P J L M ^a   Caspi, Avi ^a   Ruzyllo, Witold ^a   Borer, Jeffrey S ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Congestive heart failure; Peripheral arterial disease; Prostaglandins

Indexed keywords

PLACEBO; PROSTAGLANDIN E1;

ADULT; AGED; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HEART ARRHYTHMIA; HEART LEFT VENTRICLE FUNCTION; HEMODYNAMIC PARAMETERS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PAIN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; ARTICLE; DRUG EFFECT; HEMODYNAMICS; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ALPROSTADIL; ARTERIAL OCCLUSIVE DISEASES; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; VENTRICULAR FUNCTION, LEFT;

EID: 0030702059     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-199711000-00005     Document Type: Conference Paper

References (42)

1. 1 infusion in unstable angina: effects on anginal frequency and cardiac function. Am Heart J 1984;108:863.
2. 1 - a new therapy for refractory right heart failure and pulmonary hypertension after mitral valve replacement. J Thorac Cardiovasc Surg 1985;89:567-572.
3. 1 infusion in patients with acute myocardial infarction and left ventricular failure. Am Heart J 1982;103:485.
4. Bergström S Carlson LA, Weeks JR: The prostaglandins: a family of biological active lipids. Pharmacol Rev 1968; 20:1-48.
5. 1 infusion for small vessel arterial ischemia. J Cardiovasc Surg 1983;24:503-508.
6. 1 in atherosclerotic man. Clin Res 1984;32:186A.
7. 1-α-CD) on the experimental model of acute arterial obstruction: relating to its vasodilator and anti-platelet aggregating actions. Oyo Yakuri 1979;17:1043-1060.
8. 2-α on neutrophil aggregation. Prostaglandins 1979;17:201-210.
9. Yamaguchi H, Ishimaru S, Hakoshima A, Furukawa K, Takahashi M: Therapeutic study of reduced red cell deformability in peripheral vascular disease. In: 3rd German-Japanese Congress on Angiology (Ed. Maurer J), Demeter-Verlag, Gräfelfing, Germany, 1985, pp 342-344.
10. 2. J Pharmacol Exp Ther 1982;222:544-549.
11. 1 in Atherosclerosis (Eds. Sinzinger H, Rogatti W), Springer-Verlag, Belin, 1986, pp 39-48.
12. Campbell WB: Lipid-derived autacoids: eicosanoids and platelet-activating factor. In: Pharmacological Basis of Therapeutics (Eds. Gilman AG, Rall TW, Nies AS, Taylor P), MacMillan, New York, 1990, pp 600-617.
13. 1 in patients with peripheral vascular disease. Adv Prostaglandin Thromboxane Leukotriene Res 1976; 1:429-432.
14. 1 infusions in occlusive arterial disease stage III/IV. Vasa 1989; 28(Suppl):31-38.
15. 1 in patients with critical leg ischemia. In: Critical Limb ischemia: Diagnosis and Treatment (Eds. Horsch S, Claeys L), Steinkopff, Darmstadt, Germany, 1995, pp 29-44.
16. 1 (Eds. Diehm C, Sinzinger H, Rogatti W), Springer, Berlin, 1991, pp 21-32.
17. 1 (Eds. Diehm C, Sinzinger H, Rogatti W), Springer, Berlin, 1991, pp 49-57.
18. 1 (Eds. Diehm C, Sinzinger H, Rogatti W), Springer, Berlin, 1991, pp 91-100.
19. Borer JS, Bacharach SL, Green MV, Kent KM, Johnston GS, Epstein SE: Real-time radionuclide cineangiography during exercise in coronary artery disease. N Engl J Med 1977;296:839-844.
20. Feigenbaum H: Clinical applications of echocardiography. Prog Cardiovasc Dis 1972;14:531-558.
21. Lumly P, Humphrey PPA, Kennedy I, Coleman RA: Comparison of the potencies of some prostaglandins as vasodilators in three vascular beds of the anaesthetised dog. Eur J Pharmacol 1982;81:421-430.
22. 1 on canine hindlimb blood flow distribution. Surgery 1984;96:35-41.
23. Forst H, Fujita Y, Racenberg J, Brückner UB, Weiss T, Sunder-Plassmann L, Meßmer K: Skelettmuskeldurchblutung bei arterieller Verschlusskrankheit: Wirkung verschiedener Therapieverfahren. In: Die Mikrozirkulation des Skelettmuskels (Eds. Hammerson H, Meßmer K), Karger-Verlag, Basel, Switzerland, 1984, pp 119-135.
24. 1 in severe peripheral vascular disease. Lancet 1973;1:155-156.
25. 1 in Atherosclerosis (Eds. Sinzinger H, Rogatti W), Springer-Verlag, Berlin, 1986, pp 22-31.
26. George JN, Käser-Glanzmann R, Kallabora M, Lüscher EF: Adenosine 3′5′-cyclic monophosphate (cAMP) stimulation of active calcium trnasport by a membrane fraction from human platelets: a possible controlling mechanism of platelet function. Blood 1976;48:1007.
27. Schrör K: Prostaglandine und verwandte Verbindungen. Thieme-Verlag, Stuttgart, Germany, 1984.
28. Skehar NC: Effect of eight prostaglandins on platelet aggregation. J Med Chem 1970;13:39-44.
29. 2 on lipolysis platelet aggregation smooth muscle and the cardiovascular system. J Pharm Pharmacol 1969;21:103-108.
30. Vane JR: Prostacyclin in the cardiovascular system in health and disease. In: Prostaglandins and Other Eicosanoids in the Cardiovascular System (Ed. Schrör K), Karger-Verlag, Basel, Switzerland, 1985, pp 7-28.
31. Weichert W, Grun H, Müther B, Steinhoff W, Breddin HK: Effects of prostaglandins on platelet function and laser induced thrombous formation in rat mesenteric arterioles. In: Prostaglandins and Other Eicosanoids in the Cardiovascular System (Ed. Schrör K), Karger-Verlag, Basel, Switzerland, 1985, pp 303-309.
32. 2 inhibit function of inflammatory cells. Adv Prostagandin Thromboxane Res 1980;8:1637-1653.
33. 2-α. Prostaglandins 1977;13:281-309.
34. 2 on the human erythrocyte as monitored by spin labels. Biochem Biophys Res Commun 1974;56:478-483.
35. 1 am Ischämiemodell. Klin Wochenschr 1986;64(Suppl):257.
36. 1 infusion. Int Angio 1984;3(Suppl):105-110.
37. 1 auf Hämodynamik und Extremitätenstoflwechsel bei Gesunden und Patienten mit arterieller Verschlusskrankheit Stadium III and IV. Vasa 1985;14:220-224.
38. 1 decreases activation of arterial smooth-muscle cells. Lancet 1986;II:156-157.
39. 1 in Atherosclerosis (Eds. Sinzinger H, Rogatti W), Springer-Verlag, Berlin, 1986, pp 32-38.
40. 1 infusion after angioplasty in humans inhibits abrupt occlusion and early restenosis. Adv Prostaglandin Thromboxane Leukotriene Res 1987;17A:266-270.
41. 1 adminstration in unstable angina patients undergoing PTCA: preliminary results. Eur Heart J 1990;11(Suppl):378.
42. 1 in heart disease: review and perspective. Am J Ther 1997;4:353-358.